الصفحة الرئيسية>>Peptides>>Adrenomedullin (AM) (1-52), human

Adrenomedullin (AM) (1-52), human (Synonyms: Human adrenomedullin-(1-52)-NH2)

رقم الكتالوجGC33955

Adrenomedullin (AM) (1-52) ، الإنسان عبارة عن ببتيد مكون من 52 حمض أميني ، والذي يؤثر على تكاثر الخلايا وتكوين الأوعية في السرطان.

Products are for research use only. Not for human use. We do not sell to patients.

Adrenomedullin (AM) (1-52), human التركيب الكيميائي

Cas No.: 148498-78-6

الحجم السعر المخزون الكميّة
500μg
295٫00
متوفر
1mg
478٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Adrenomedullin (AM) (1-52), human is a 52-amino acid peptide, which affects cell proliferation and angiogenesis in cancer.

To explore the effect of Adrenomedullin (AM) (1-52), human on astroglioma cells, CRT-MG cells are incubated in the absence or presence of Adrenomedullin (AM) (1-52), human (ADM1-52) for 48 h in a medium containing 1% FBS, and wound-healing assay is performed. The number of cells migrating to the wound region significantly increases in the ADM1-52-treated cells, in a dose-dependent manner, compared to the untreated cells[1].

[1]. Lim SY, et al. Transcriptional regulation of adrenomedullin by oncostatin M in human astroglioma cells: implications for tumor invasion and migration. Sci Rep. 2014 Sep 23;4:6444.

مراجعات

Review for Adrenomedullin (AM) (1-52), human

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Adrenomedullin (AM) (1-52), human

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.